Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Germany’s Boehringer Ingelheim is entering into a strategic alliance with Shanghai-based Zhangjiang Biotech & Pharmaceutical Base Development Company (ZJ Base Company) to construct a cGMP biopharmaceuticals facility in China. Scheduled to commence operations early in 2016, the new facility will be the first to use mammalian cell culture technology in the production of biopharmaceuticals in China. Set to carry out technical process development and cGMP manufacturing, the new facility will offer a range of development and clinical services. Boehringer Shareholders Committee chairman Christian said, “Shanghai is our ideal partner with its advantages in investment environment, service system and talent resources.”
Help employers find you! Check out all the jobs and post your resume.
